30 reports

  • PANCREATIC CANCER THERAPEUTICS, EFFICACY AND SAFETY RESULTS FOR KEY PARAMETERS - PIPELINE AND MARKETED PRODUCTS (LIGHT
  • PANCREATIC CANCER THERAPEUTICS, GLOBAL, DEVELOPMENTAL PIPELINE, PRECLINICAL 2015

Genetic Risk for Alcoholic Chronic Pancreatitis.

  • Pancreatic Cancer
  • World
  • Forecast
  • Market Size
  • Celgene Corporation

Pancreatic cancer

4546 5000 3864
  • HYPERACUTE-PANCREAS DRUG PROFILE
  • PRODUCT PROFILE (LATE STAGE): HYPERACUTE-PANCREAS

THERE ARE A RANGE OF INHERITED GENETIC SYNDROMES IMPLICATED IN INCREASED PANCREATIC CANCER RISK A number of inherited genetic syndromes and/ or gene mutations have been implicated in an increased risk of developing pancreatic cancer.

  • Pancreatic Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.

MGH is # ## in the Nation.

  • Artificial Intelligence
  • Healthcare
  • Hospital
  • Information Technology
  • Pancreatic Cancer
  • VARIATION BY GEOGRAPHY/ETHNICITY

Table ##.

  • Cancer
  • Pancreatic Cancer
  • Pathology

WHIM is a genetic primary immunodeficiency disease caused by the abberant trafficking of specific immune cells that are critical for proper immune system functions.

  • Pancreatic Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

In theory, Ampligen induced crossprotection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Pancreatic Cancer
  • Therapy
  • Vaccine
  • Canada
  • Hemispherx Biopharma, Inc.

Each ADS represents the right to receive one ordinary share.

  • Pancreatic Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Erytech Pharma SA
  • OCT 24, 2016: PHARMACYTE BIOTECH SELECTS DR. MANUEL HIDALGO AS PRINCIPAL INVESTIGATOR FOR ITS PANCREATIC CANCER CLINICAL TRIAL
  • NOV 01, 2016: PHARMACYTE BIOTECH REQUESTS PRE-IND MEETING WITH FDA FOR ITS PANCREATIC CANCER CLINICAL TRIAL

Efforts to identify the genetic code for the responsible enzyme in these cell lines are underway.

  • Marijuana
  • Pancreatic Cancer
  • United States
  • Company
  • PharmaCyte Biotech, Inc.
  • ITALY PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET,
  • 6.3 BY GEOGRAPHY

One such case is the use of Ipilimumab.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • World
  • Market Size

In theory, Ampligen induced crossprotection may extend to any vaccine for viruses subject to a high mutation rate and genetic drift.

  • Biopharmaceutical
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Hemispherx Biopharma, Inc.

The poster entitled ' PIM## Inhibitor as a Targeted Therapy for the Treatment of Multiple Myeloma Patients with Specific Genetic Signatures', will be presented on April ##, 2013.

  • Pancreatic Cancer
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT DESCRIPTION
  • DIAGNOSTIC BIOMARKER - PANCREATIC CANCER - PRODUCT STATUS

CLINICAL GENETIC TEST VOLUME(##) GREW ##% DRIVEN BY THE INCLUSION OF CLARIENT' S RESULTS IN THE CONSOLIDATED TOTAL.

  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • United States
  • Proteome Sciences
  • Clinical Trial profile. 2315 Trial Title
  • 5. All the trials included are unique trials.

The researchers analyzed genetic, tumor micro-environmental, and immunologic factors in tumors derived from a transgenic model of breast cancer.

  • Clinical Trial
  • Drug Discovery And Development
  • Pancreatic Cancer
  • Pharmaceutical
  • World

NA : Not Available Source: Global Markets Direct harbor a specific genetic lesion in the gene Neurofibromatosis Type ## (NF##), which results in the loss of the protein Merlin and increased sensitivity to FAK inhibition.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • Verastem, Inc.

ARQ ## is being dosed in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR## genetic alterations as part of the phase ## portion of a biomarker driven phase ##/ ## trial.

  • Drug Discovery And Development
  • Hepatitis
  • Pancreatic Cancer
  • World
  • Product Initiative

In June 2006, Insmed Incorporated Limited has withdrawn orphan drug designation for mecasermin rinfabate for the treatment of growth hormone deficiency and primary insulin-like growth factor-## deficiency due to molecular or genetic defects.

  • Cancer
  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative

ADALTA LTD Ambrx Inc (Ambrx) is a biopharmaceutical company which focuses on the discovery and development of proteinbased medicines by using its expanded genetic code.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.

The prominent features of this report are - ##.

  • Lung Cancer
  • Pancreatic Cancer
  • World
  • Product Initiative
  • Eli Lilly & Co.
  • NECUPARANIB - DRUG PROFILE
  • CELLULAR IMMUNOTHERAPY TO TARGET GM-CSFR FOR PANCREATIC CANCER - DRUG PROFILE

The clinical responses have been independent of high-risk clinical or genetic features.

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

## Alzheimer' s Disease ## Amyotrophic Lateral Sclerosis ## Chronic Renal Failure ## Coronary Artery Disease ## Depression ## Diabetic Retinopathy ## Duchenne Muscular Dystrophy ## Heart Failure ## Liver Fibrosis ##

  • Dementia
  • Mental Health
  • Pancreatic Cancer
  • Pathology
  • SomaLogic, Inc.
  • Heparanase (Endo-Glucoronidase or Heparanase-1 or EC 3.2.1.166) - Featured News & Press Releases

M## extended survival of a genetically engineered mouse model for pancreatic cancer when it was combined with the current standard of care chemotherapy gemcitabine.

  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • Progen Pharmaceuticals Limited
  • COURTAGEN LIFE SCIENCES, INC. PIPELINE PRODUCTS SUMMARY BY DEVELOPMENT STAGE DEVELOPMENTAL STAGE

" There are a large number of patients who suffer from non-genetic forms of epilepsy or seizures, or may not need a genetic diagnosis, but who are being treated with anticonvulsants.

  • Breast Cancer
  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Courtagen Life Sciences, Inc.
  • DORMANT PROJECTS (CONTD..4), H2 2016

## deficiency due to molecular or genetic defects from EU Community register.

  • Chemotherapy
  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative

The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement. - What survival benefits do current therapies provide?

  • Cancer
  • Pancreatic Cancer
  • Pathology
  • Deals & Alliance

Sickle cell disease is one of the most prevalent genetic disorders in the U. S.

  • Pancreatic Cancer
  • Therapy
  • United States
  • World
  • Product Initiative
  • CHARIS-1000 - DRUG PROFILE
  • CELLULAR IMMUNOTHERAPY TO TARGET GM-CSFR FOR PANCREATIC CANCER - DRUG PROFILE

The clinical responses have been independent of high-risk clinical or genetic features.

  • Cancer
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative

ALS patients received riluzole plus masitinib ##. ## mg/ kg/ day, ##. ## mg/ kg/ day, or placebo (##:##:##) up to ## weeks.

  • Cancer
  • Pancreatic Cancer
  • United States
  • World
  • Product Initiative

M## extended survival of a genetically engineered mouse model for pancreatic cancer when it was combined with the current standard of care chemotherapy gemcitabine.

  • Eye Disease
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Ohr Pharmaceutical Inc.

Its products are also used for the treatment of certain rare genetic disorders of the immune system.

  • Pancreatic Cancer
  • Renal Cancer
  • Research And Development
  • Therapy
  • BioLineRx Ltd.
  • COURTAGEN LIFE SCIENCES, INC. PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW
  • PANCREATIC CANCER DIAGNOSTIC PANEL - PRODUCT DESCRIPTION

Its products are used to treat oncology and genetic disease.

  • Drug Discovery And Development
  • Pancreatic Cancer
  • United States
  • Company
  • GlobalData's company